Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15304MR)

This product GTTS-WQ15304MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Allergic asthma, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15304MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11399MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ10736MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ5019MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ6205MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ3281MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ12150MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ945MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ11353MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW